LivaNova (NASDAQ:LIVN) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research report sent to investors on Wednesday, Stock Target Advisor reports. They currently have a $88.00 price target on the stock.
LIVN has been the topic of a number of other reports. BidaskClub raised LivaNova from a sell rating to a hold rating in a research report on Thursday, November 7th. BTIG Research reiterated a hold rating on shares of LivaNova in a report on Wednesday, July 31st. ValuEngine upgraded LivaNova from a hold rating to a buy rating in a report on Thursday, November 7th. Piper Jaffray Companies set a $90.00 price target on LivaNova and gave the company a buy rating in a report on Friday, September 6th. Finally, Berenberg Bank reiterated a buy rating and set a $114.00 price target on shares of LivaNova in a report on Monday, September 9th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. LivaNova presently has an average rating of Buy and a consensus price target of $97.67.
Shares of LivaNova stock traded up $0.66 on Wednesday, reaching $79.58. 335,700 shares of the company were exchanged, compared to its average volume of 478,894. The stock has a fifty day moving average price of $73.53 and a 200-day moving average price of $74.80. The firm has a market capitalization of $3.79 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 3.57 and a beta of 0.53. The company has a current ratio of 1.17, a quick ratio of 0.81 and a debt-to-equity ratio of 0.21. LivaNova has a fifty-two week low of $64.80 and a fifty-two week high of $103.90.
In other news, Director Daniel Jeffrey Moore sold 1,500 shares of LivaNova stock in a transaction on Monday, September 16th. The stock was sold at an average price of $84.56, for a total transaction of $126,840.00. Also, CEO Damien Mcdonald sold 1,000 shares of LivaNova stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $77.00, for a total value of $77,000.00. Following the transaction, the chief executive officer now owns 60,774 shares in the company, valued at approximately $4,679,598. The disclosure for this sale can be found here. Insiders have sold 4,500 shares of company stock worth $351,360 in the last quarter. 0.41% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Texas Permanent School Fund grew its stake in LivaNova by 0.4% in the third quarter. Texas Permanent School Fund now owns 32,937 shares of the company’s stock valued at $2,430,000 after purchasing an additional 143 shares in the last quarter. US Bancorp DE grew its stake in LivaNova by 11.5% in the second quarter. US Bancorp DE now owns 1,452 shares of the company’s stock valued at $104,000 after purchasing an additional 150 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in LivaNova by 8.9% in the second quarter. Nisa Investment Advisors LLC now owns 1,900 shares of the company’s stock valued at $137,000 after purchasing an additional 155 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in LivaNova by 1.4% in the second quarter. Oregon Public Employees Retirement Fund now owns 19,726 shares of the company’s stock valued at $1,419,000 after purchasing an additional 278 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in LivaNova by 3.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,994 shares of the company’s stock valued at $575,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 88.52% of the company’s stock.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.